News articles about Syros Pharmaceuticals (NASDAQ:SYRS) have been trending somewhat positive recently, according to Accern. The research firm identifies positive and negative press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Syros Pharmaceuticals earned a media sentiment score of 0.16 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 46.6422931382454 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Several brokerages have commented on SYRS. BidaskClub upgraded Syros Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday. HC Wainwright reiterated a “hold” rating and set a $10.00 price target on shares of Syros Pharmaceuticals in a report on Wednesday, March 14th. Zacks Investment Research downgraded shares of Syros Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, January 11th. Wedbush restated an “outperform” rating and issued a $13.00 price objective (up previously from $11.00) on shares of Syros Pharmaceuticals in a research note on Tuesday, March 13th. Finally, Oppenheimer set a $28.00 price objective on shares of Syros Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, January 8th. One analyst has rated the stock with a sell rating, three have issued a hold rating and seven have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $21.13.
Shares of Syros Pharmaceuticals (NASDAQ:SYRS) traded down $0.34 during trading on Friday, hitting $12.45. 115,947 shares of the stock traded hands, compared to its average volume of 258,415. The firm has a market capitalization of $410.47, a P/E ratio of -5.87 and a beta of -2.26. Syros Pharmaceuticals has a twelve month low of $6.30 and a twelve month high of $24.38.
In other Syros Pharmaceuticals news, Director Srinivas Akkaraju purchased 209,424 shares of the firm’s stock in a transaction on Wednesday, January 31st. The shares were purchased at an average price of $9.55 per share, for a total transaction of $1,999,999.20. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 33.60% of the stock is owned by insiders.
WARNING: “Syros Pharmaceuticals (SYRS) Given Media Sentiment Rating of 0.16” was reported by BBNS and is the property of of BBNS. If you are accessing this piece on another website, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be read at https://baseballnewssource.com/2018/03/24/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-syros-pharmaceuticals-syrs-stock-price/1986228.html.
Syros Pharmaceuticals Company Profile
Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.